HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Iris L K Wong Selected Research

Flavonoids

1/2023Amine-Linked Flavonoids as Agents Against Cutaneous Leishmaniasis.
10/2021Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2).
1/2019Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors.
11/2018Discovery of Novel Flavonoid Dimers To Reverse Multidrug Resistance Protein 1 (MRP1, ABCC1) Mediated Drug Resistance in Cancers Using a High Throughput Platform with "Click Chemistry".
10/2015A New Class of Safe, Potent, and Specific P-gp Modulator: Flavonoid Dimer FD18 Reverses P-gp-Mediated Multidrug Resistance in Human Breast Xenograft in Vivo.
6/2014In vitro and in vivo efficacy of novel flavonoid dimers against cutaneous leishmaniasis.
3/2012Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.
9/2009Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives.
4/2009Flavonoid dimers as bivalent modulators for p-glycoprotein-based multidrug resistance: structure-activity relationships.
3/2007Flavonoid dimers as bivalent modulators for pentamidine and sodium stiboglucanate resistance in leishmania.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Iris L K Wong Research Topics

Disease

21Neoplasms (Cancer)
02/2023 - 11/2006
15Breast Neoplasms (Breast Cancer)
02/2023 - 11/2006
3Leukemia
02/2023 - 11/2006
2Cutaneous Leishmaniasis
01/2023 - 06/2014
2Infections
10/2019 - 02/2019
2Leishmaniasis
06/2014 - 03/2007
1Body Weight (Weight, Body)
10/2022
1Visceral Leishmaniasis (Kala Azar)
06/2014
1Carcinoma (Carcinomatosis)
09/2009

Drug/Important Bio-Agent (IBA)

11FlavonoidsIBA
01/2023 - 11/2006
9Member 1 Subfamily B ATP Binding Cassette TransporterIBA
02/2023 - 11/2006
8Proteins (Proteins, Gene)FDA Link
10/2022 - 03/2012
5Doxorubicin (Adriamycin)FDA LinkGeneric
02/2023 - 11/2006
5Paclitaxel (Taxol)FDA LinkGeneric
02/2023 - 11/2006
5ningalin BIBA
01/2017 - 07/2010
3multidrug resistance-associated protein 1IBA
11/2018 - 09/2009
3Vincristine (Oncovin)FDA LinkGeneric
10/2015 - 11/2006
3Vinblastine (Vinblastine Sulfate)FDA Link
10/2015 - 11/2006
3ApigeninIBA
06/2009 - 11/2006
2Catechin (Z 7300)IBA
02/2023 - 12/2021
2AminesIBA
01/2023 - 08/2014
2gallocatechol (epigallocatechin)IBA
12/2021 - 06/2015
2Daunorubicin (Cerubidine)FDA LinkGeneric
10/2015 - 11/2006
2Ethylene Glycol (Monoethylene Glycol)IBA
04/2009 - 11/2006
1Topotecan (Hycamtin)FDA LinkGeneric
10/2022
1Peptides (Polypeptides)IBA
01/2021
1Micrococcal NucleaseIBA
01/2021
1Oncogene Proteins (Oncogene Protein)IBA
01/2021
1Phenobarbital (Luminal)FDA Link
10/2020
1VimentinIBA
10/2020
1Progesterone Receptors (Progesterone Receptor)IBA
10/2020
1Antimicrobial PeptidesIBA
10/2019
1Cefuroxime (Zinacef)FDA LinkGeneric
02/2019
1Anti-Bacterial Agents (Antibiotics)IBA
02/2019
1TriazolesIBA
01/2019
1Mitoxantrone (Novantrone)FDA LinkGeneric
10/2015
1dihydromyricetinIBA
06/2015
1PiperazineIBA
10/2014
1QuercetinIBA
08/2012
1Etoposide (VP 16)FDA LinkGeneric
09/2009
1Pentamidine (NebuPent)FDA LinkGeneric
06/2009
1Quinacrine (Mepacrine)IBA
06/2009
1Adenosine Triphosphate (ATP)IBA
03/2007
1ATP-Binding Cassette Transporters (ABC Transporters)IBA
03/2007

Therapy/Procedure

4Therapeutics
02/2023 - 01/2019
2Drug Therapy (Chemotherapy)
10/2022 - 06/2014
1Intralesional Injections
01/2023
1Combination Drug Therapy (Combination Chemotherapy)
12/2022